Obama's $215 million Precision Medicine Initiative launched

2 February 2015
washingtondc

A new Precision Medicine Initiative will revolutionize personalized medicine in the USA, helped by voluntary data sharing by more than one million Americans.

On Friday, US President Barack Obama gave more details about the scheme which he announced during his State of the Union speech last month. The $215 million program is part of the President’s budget for 2016. This includes $130 million going to the National Institutes of Health (NIH), $70 million to the National Cancer Institute, $10 million to the US Food and Drug Administration and $5 million to the Office of the National Coordinator for Health Information Technology.

The NIH said that precision medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person. While significant advances in precision medicine have been made for select cancers, the practice is not currently in use for most diseases. The new initiative aims to revolutionize medicine and generate the scientific evidence needed to move the concept of precision medicine into everyday clinical practice.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical